March 5, 2024Gate Neurosciences demonstrates zelquistinel preclinical efficacy and therapeutic potential in autism spectrum disorders in new peer-reviewed studyRead full post
January 24, 2024Gate Neurosciences announces clinical collaboration with beacon biosignals to advance precision EEG biomarkers in major depressive disorderRead full post
November 7, 2023Gate Neurosciences announces positive topline human EEG biomarker results demonstrating dose-dependent target activation in phase 1 study of apimostinelRead full post
May 23, 2023Gate Neurosciences to highlight new biomarker data & host R&D day at 2023 ASCP annual meetingRead full post
May 3, 2023Gate Neurosciences hones in on precision medicine with expanded research operations supporting its synaptic function-enhancing moleculesRead full post
November 29, 2022Gate Neurosciences doses first subject in a translational EEG biomarker study of apimostinel, a rapid-acting treatment for acute depressive disorderRead full post
Duman (2020): Positive NMDAR modulation by Zelquistinel exerts rapid antidepressant-like effects via excitatory neurons
Zanos (2023): NMDAR activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine
Donello (2022): Zelquistinel is a novel oral NMDAR PAM exhibiting rapid and sustained antidepressant-like effects
